Congratulations to our client, Ascendis Pharma on their appointment of Dr. Jethro Ekuta to the role of Chief Regulatory Officer, Head of Global Regulatory Affairs & Pharmacovigilance.
Ascendis Pharma (NASDAQ:ASND) is applying their innovative TransCon technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by core values of patients, science and passion, they utilize their TransCon technology platform to create new and potentially best-in-class therapies. Ascendis has two commercial products YORVIPATH and SKYTROFA as well as numerous products in development within the endocrine rare disease and oncology therapeutic areas.
Dr Jethro Ekuta has 30 years of regulatory affairs and drug safety experience in medium and large pharmaceutical organizations, including having spent time at the FDA. Prior to joining Ascendis, he served as the Vice President, Global Regulatory Affairs at Alexion Pharmaceuticals Inc (a wholly owned subsidiary of AstraZeneca). Throughout his career, he has held leadership roles at leading pharmaceutical companies such as Horizon Pharma, Johnson & Johnson, Genzyme, Bristol Myers Squibb, and Procter & Gamble. He began his career as a special government employee and fellow in clinical pharmacology in the FDA’s Office of Clinical Pharmacology and Biopharmaceutics. Jethro is the Chair of the Board of Directors for the Regulatory Affairs Professionals Society (RAPS). He holds a PhD in Pharmacology and Toxicology from The University of Mississippi, and a DVM from Ahmadu Bello University in Zaria, Nigeria.
C1 Team: Christos Richards and James Reynolds